New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
06:07 EDTACORAcorda Therapeutics reports FDA issues CRL for Plumiaz
Acorda Therapeutics announced that the FDA has issued a Complete Response Letter, or CRL, for the New Drug Application for Plumiaz Nasal Spray for the treatment of people with epilepsy who experience cluster seizures. A CRL is a communication from the FDA that informs a company that their review of the NDA is complete and the application cannot be approved in its present form. The company is currently developing a response to address the items outlined in the letter.
News For ACOR From The Last 14 Days
Check below for free stories on ACOR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
06:24 EDTACORAcorda Therapeutics backs FY14 R&D $60M-$70M
Subscribe for More Information
06:24 EDTACORAcorda Therapeutics reports Q2 Ampyra revenue $87.4M
Subscribe for More Information
06:23 EDTACORAcorda Therapeutics reports Q2 GAAP EPS 11c, consensus 15c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use